Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of teclistamab versus PVd or Kd in relapsed or refractory multiple myeloma
MOH_2022-12-13_012232Phase 3Active, not recruiting
- Sponsor
- Johnson & Johnson
- Start
- Nov 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of teclistamab, sponsored by Johnson & Johnson. Started Nov 2022; status: active, not recruiting.
02
Drugs
teclistamab
Beyond the preview
Go deeper on MOH_2022-12-13_012232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-13_012232.